title: Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?
abstract: P-glycoprotein is one of the most well-studied drug transporters, significant for its role in cancer multiple drug resistance. However, using P-gp inhibitors with the aim of enhancing the therapeutic efficacy of anti-cancer drugs has led to disappointing outcomes. Furthermore, several lead compounds suggested by in vitro and pre-clinical studies have shown variable pharmacokinetics and therapeutic efficacies when applied in the clinical setting. This review will highlight the need to revisit a sound approach to better design and apply P-gp inhibitors in light of safety and efficacy. Challenges confronting the issue hinge upon myriad studies that do not necessarily represent the heterogeneous target population of this therapeutic approach. The application of P-gp modulators has also been complicated by the promiscuous substrate-binding behaviour of P-gp, as well as toxicities related to its intrinsic presence in healthy tissue. This review capitalizes on information spanning genetics, energetics, and pharmacology, bringing to light some fundamental aspects that ought to be reconsidered in order to improve upon and design the next generation of P-gp inhibitors.
authors.affiliation: Cellular Therapeutics Center, Makati Medical Center Makati City, Philippines 1229.
authors.forename: Francisco S
authors.initials: FS
authors.lastname: Chung
authors.affiliation: Cellular Therapeutics Center, Makati Medical Center Makati City, Philippines 1229.
authors.forename: Jayson S
authors.initials: JS
authors.lastname: Santiago
authors.affiliation: Cellular Therapeutics Center, Makati Medical Center Makati City, Philippines 1229.
authors.forename: Miguel Francisco M De
authors.initials: MF
authors.lastname: Jesus
authors.affiliation: Cellular Therapeutics Center, Makati Medical Center Makati City, Philippines 1229.
authors.forename: Camille V
authors.initials: CV
authors.lastname: Trinidad
authors.affiliation: Cellular Therapeutics Center, Makati Medical Center Makati City, Philippines 1229.
authors.forename: Melvin Floyd E
authors.initials: MF
authors.lastname: See
keywords: Cancer therapeutics; P-glycoprotein; drug resistance; energetics; pharmacokinetics; transporter